HCPCS Code M1412
Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
| Short Description | Met nsclc w/ egfr alk oth ab |
|---|---|
| Year | 2026 |
| Coverage Code | C = Carrier judgment |
| Action Code | N = No maintenance for this code |
| Action Effective Date | January 01, 2025 |
| Code Added Date | January 01, 2025 |
| Pricing Indicator | 00 = Service not separately priced by Part B (e.g., services not covered, bundled, used by part a only, etc.) |
| Type of Service | 1 = Medical care |